Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.
Controlling more than $13bn of its clients’ money, Deerfield Management is an investment firm focused on healthcare investments, including ventures covering the pharmaceutical, biotech, medical device and healthcare services sectors.
Recent medtech-related deals of note funded by Deerfield include Happify Health’s $73m series D financing round, the SPAC-enabled merger...
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
